Human retroviruses: Their role in cancer

Proceedings of the Association of American Physicians

Volumn 111, Issue 6, 1999, Pages 563-572

  Blattner, W A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

ATL; HIV 1; HTLV I; Kaposi's sarcoma; NHL; Retroviral malignancies

Indexed keywords

ANTHRACYCLINE; ANTIRETROVIRUS AGENT; BLEOMYCIN; CHORIONIC GONADOTROPIN; CIDOFOVIR; DAUNORUBICIN; DOXORUBICIN; FOSCARNET; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IM 862; INTERLEUKIN 2; PACLITAXEL; PENTOXIFYLLINE; SEMAXANIB; THALIDOMIDE; TPN 470; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANGIOSARCOMA; ANUS CARCINOMA; CARCINOGENICITY; HERPES VIRUS; HODGKIN DISEASE; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS; KAPOSI SARCOMA; LUNG SMALL CELL CANCER; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; RETROVIRUS; REVIEW; SEMINOMA; T CELL LEUKEMIA; T CELL LYMPHOMA; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

EID: 0032746002     PISSN: 1081650X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1381.1999.99210.x     Document Type: Review

References (31)

1. 1 Pisani P., Parkin D.M., Muñoz N., Ferlay J. Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev. 6: 387 400, 1997.
2. 2 Feigal E.G. AIDS‐associated malignancies: Research perspectives. Biochim. Biophys. Acta 1423: C1 C9, 1998.
3. 3 Gallo R.C. The enigmas of Kaposi's sarcoma. Science 282: 1837 1839, 1998.
4. 4 Blattner W.A., O'Brien T.R., and Mueller N.E. Retroviruses—human immunodeficiency virus. In: Evans A.S. and Kaslow R.A. (eds). Viral Infections of Humans: Epidemiology and Control. New York: Plenum Medical Books, 1997. Pp. 713–783.
5. 5 Dan S., Tanimura A., Yoshida M. Interaction of Gli2 with CREB protein on DNA elements in the long terminal repeat of human T‐cell leukemia virus type 1 is responsible for transcriptional activation by tax protein. J. Virol. 73: 3258 3263, 1999.
6. 6 Wodarz D., Nowak M.A., Bangham C.R.M. The dynamics of HTLV‐I and the CTL response. Immunol. Today 20: 220 227, 1999.
7. 7 Mulloy J.C., Kislyakova T., Cereseto A., et al. Human T‐cell lymphotropic/leukemia virus type 1 Tax abrogates p53‐induced cell cycle arrest and apoptosis through its CREB/ATF functional domain. J. Virol. 72: 8852 8860, 1998.
8. 8 Yoshida H., Nagano Y., Isono T., Seto A. Persistence and differentiation of HTLV‐I‐transformed immature T‐cells in HTLV‐I carrier rabbits. Leuk. Res. 21: 1051 1059, 1997.
9. 9 Suzuki T. & Yoshida M. HTLV‐1 Tax protein interacts with cyclin‐dependent kinase inhibitor p16Ink4a and counteracts its inhibitory activity to CDK4. Leukemia 11: 14 16, 1997.
10. 10 Yoshida M. Howard Temin Memorial Lectureship. Molecular biology of HTLV‐1: Deregulation of host cell gene expression and cell cycle. Leukemia 11: 1 2, 1997.
11. 11 Blattner W.A. and de Oliveira M.S.P. Human T‐lymphotrophic viruses: HTLV‐I and HTLV‐II. In: Merigan T.C., Bartlett J.G. Jr., and Bolognesi D. (eds). Textbook of AIDS Medicine. Baltimore: Williams & Wilkens, 1999. Pp. 1003–1029.
12. 12 Mann D.L., Desantis P., Mark G., et al. HTLV‐I‐associated B‐cell CLL: Indirect role for retrovirus in leukemogenesis. Science 236: 1103 1106, 1987.
13. 13 Goedert J.J., Cote T.R., Virgo P., et al. Spectrum of AIDS‐associated malignant disorders. Lancet 351: 1833 1839, 1998.
14. 14 Chang Y., Cesarman E., Pessin M.S., et al. Identification of herpesvirus‐like DNA sequences in AIDS‐associated Kaposi's sarcoma [see comments]. Science 266: 1865 1869, 1994.
15. 15 Jones J.L., Hanson D.L., Dworkin M.S., et al. Effect of antiretroviral therapy on recent trends in cancers among HIV‐infected persons. J. Acquir. Immune Defic. Syndr. 21: 223 227, 1999.
16. 16 Kledal T.N. A broad‐spectrum chemokine antagonist encoded by Kaposi's sarcoma‐associated herpesvirus. Science 277: 1656 1659, 1997.
17. 17 Gao S.J., Kingsley L., Hoover D.R., et al. Seroconversion to antibodies against Kaposi's sarcoma‐associated herpesvirus‐related latent nuclear antigens before the development of Kaposi's sarcoma. N. Engl. J. Med. 335: 233 241, 1996.
18. 18 Gill P.S. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. J. Clin. Oncol. 14: 2353 2364, 1996.
19. 19 Little R., Welles L., Wyvill K., et al. Preliminary results of a Phase II study of oral thalidomide in patients with AIDS‐related Kaposi's sarcoma [abstract 18]. 2nd National AIDS Malignancy Conference. Bethesda, MD, April 6–8, 1998.
20. 20 Martin J.N., Ganem D.E., Osmond D.H., et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N. Engl. J. Med. 338: 948 954, 1998.
21. 21 Medveczky M.M., Horvath E., Lund T., Medveczky P.G. In vitro antiviral drug sensitivity of the Kaposi's sarcoma‐associated herpesvirus. AIDS 11: 1327 1332, 1997.
22. 22 Miles S.A., Wang H., Elashoff R., Mitsuyasu R.T. Improved survival for patients with AIDS‐related Kaposi's sarcoma. J. Clin. Oncol. 12: 1910 1916, 1994.
23. 23 Miller G., Rigsby M.O., Heston L., et al. Antibodies to butyrate‐inducible antigens of Kaposi's sarcoma‐associated herpesvirus in patients with HIV‐infection. N. Engl. J. Med. 334: 1292 1297, 1996.
24. 24 Monini P., De Lellis L., Fabris M., et al. Kaposi's sarcoma‐associated herpesvirus DNA sequences in prostate tissue and human semen. N. Engl. J. Med. 334: 1168 1172, 1996.
25. 25 Moore P.S. & Chang Y. Detection of herpesvirus‐like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection [see comments]. N. Engl. J. Med. 332: 1181 1185, 1995.
26. 26 Ablashi D.V., Chatlynne L.G., Lapps W., et al. Human herpesvirus‐8 (HHV‐8) comparative seroprevalence in USA, India, Thailand, Malaysia, and its association with malignancies [abstract 55]. 2nd National AIDS Malignancy Conference. Bethesda, MD, April 6–8, 1998.
27. 27 Buchbinder S.P., Vittinghoff E., Colfax G., and Holmberg S. Declines in AIDS incidence associated with highly active anti‐retroviral therapy are not reflected in KS and lymphoma incidence [abstract S7]. 2nd National AIDS Malignancy Conference. Bethesda, MD, April 6–8, 1998.
28. 28 Jacobson L.P., for the Multicenter AIDS Cohort Study. Impact of highly effective anti‐retroviral therapy on the incidence of malignancies among HIV infected individuals [abstract S5]. 2nd National AIDS Malignancy Conference. Bethesda, MD, April 6–8, 1998.
29. 29 Rabkin C., Testa M.A., Fischl M.A., et al. Declining incidence of Kaposi's sarcoma in AIDS Clinical Trial Group (ACTG) trials [abstract S4]. 2nd National AIDS Malignancy Conference. Bethesda, MD, April 6–8, 1998.
30. 30 Liebowitz D. Epstein‐Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients [see comments]. N. Engl. J. Med. 338: 1413 1421, 1998.
31. 31 Luppi M., Barozzi P., Maiorana A., et al. Human herpesvirus‐8 DNA sequences in human immunodeficiency virus‐negative antioimmunoblastic lymphadenopathy and benign lymphadenopathy with giant germinal center hyperplasia and increased vascularity. Blood 87: 3903 3909, 1996.